S0003650

3TC150mg+NVP200mg+AZT300mg tabs/PAC-60


Lamivudine 150mg + Nevirapine 200mg + Zidovudine 300mg tablets, bottle pack of 60
Indicative Price : Upon Request

NOTE: The description below is for a standard product. It is not specific to patent status and pricing policies that may apply at country level. This information is available on request from Supply Division: Contact: supply@unicef.org

General Description:
Lamivudine 150mg + Nevirapine 200mg + Zidovudine 300mg tablets, bottle pack of 60

Technical Specifications:
Each film coated tablet contains Lamivudine 150mg and Nevirapine 200mg and Zidovudine 300mg in fixed dose combination.

Therapeutic class:
Nucleoside Reverse Transcriptase Inhibitors (NRTI)

Standard shelf life:
3 years

Other available formulations:
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.

Guidelines for use:
For more details, please click the links listed below:

WHO treatment guidelines


and

WHO Essential Medicines Library


or your regional national guidelines

For details about paediatric dosage schemes, please click the links listed below:

WHO HIV/AIDS


WHO Generic tool for assessing paediatric ARV dosing


Indications:
Management of HIV infection in children and adults. By mouth (oral), PO.

Storage:
Do not store above 30°C (86°F).
Store in tightly closed original container
Keep out of reach and sight of children

Dispensing instructions:
Dispense in original container. Do not repack.
The product is a fixed dose combination and cannot be used during the 2 week period of nevirapine lead-in therapy.

Regulatory status:
For latest updates, please click the links listed below:

List of WHO Prequalified Medicines


List of USFDA approved and tentatively approved items

Related Products